持続性上皮欠損管理の世界市場レポート 2025年

持続性上皮欠損管理市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は16.9％で、173億5,000万米ドルに成長します。予測期間における成長の原動力となるのは、パートナーシップや協力関係の強化、認知度の向上と教育、価値観に基づくケアの重視、糖尿病や高血圧などの疾患の有病率の上昇、早期介入と管理などです。主な動向としては、技術の発展、革新的な治療オプションに対する需要の高まり、高度な治療方法、最先端の手術ツールや技術の利用可能性、革新的な薬剤の開発などが挙げられます。

眼疾患の有病率の増加は、持続性上皮欠損管理市場の拡大を促進すると予測されています。眼疾患は、眼の構造、機能、全体的な健康に影響を与え、視力障害、不快感、失明の可能性につながる幅広い病状を包含します。人口の高齢化、長時間のスクリーン使用、環境の変化などの要因が、これらの疾患の有病率の上昇に寄与しています。持続的な上皮欠損の効果的な管理は、治癒を促進し、炎症を抑え、感染や瘢痕化などの合併症を予防するため、眼障害の治療にとって極めて重要です。例えば、2024年12月、スイスに本部を置く政府間機関である世界保健機関（WHO）は、2023年の小児近視の全体的なプール有病率は5.23％であり、男性（3.94％）に比べて女性（4.90％）の有病率が顕著に高いと報告しました。その結果、眼疾患の発生が増加しており、持続性上皮欠損管理市場の成長を後押ししています。

眼科手術の増加も持続性上皮欠損管理市場を押し上げると予想されています。眼科手術は、視力障害の矯正、疾病の治療、傷害の修復のために行われる医療処置です。このような外科手術の増加は、白内障、緑内障、屈折異常などの眼疾患の有病率の上昇に加え、外科手術技術の進歩や低侵襲手術の普及によってもたらされています。効果的な持続性上皮欠損管理は、上皮再生をサポートする標的治療を通じて角膜治癒を促進し、合併症を減らし、視力結果を向上させることで、眼科手術において重要な役割を果たしています。例えば、米国を拠点とする移植協会であるアイバンク・アソシエーション・オブ・アメリカ（Eye Bank Association of America）は、2023年には国内の角膜移植術が2.7％増加し、2022年の49,597件から50,925件に増加すると報告しています。このような眼科手術の動向が持続性上皮欠損管理市場の拡大に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界持続性上皮欠損管理PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の持続性上皮欠損管理市場：成長率分析
• 世界の持続性上皮欠損管理市場の実績：規模と成長, 2019-2024
• 世界の持続性上皮欠損管理市場の予測：規模と成長, 2024-2029, 2034F
• 世界持続性上皮欠損管理総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の持続性上皮欠損管理市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 上皮細胞または輪部
• 炎症性疾患
• 神経栄養疾患
• その他の病気の種類
• 世界の持続性上皮欠損管理市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直接販売
• オンライン薬局
• 小売薬局
• 病院
• 世界の持続性上皮欠損管理市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院または臨床検査室
• 医師の診療所
• リファレンスラボ
• その他のエンドユーザー
• 世界の持続性上皮欠損管理市場上皮性または輪部性のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 輪部幹細胞欠損症（LSCD）
• 輪部移植
• 結膜移植
• 世界の持続性上皮欠損管理市場炎症性疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドライアイ症候群
• アレルギー性結膜炎
• ぶどう膜炎
• 世界の持続性上皮欠損管理市場神経栄養疾患のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単純ヘルペスウイルス（HSV）角膜炎
• 糖尿病性神経障害
• 神経栄養性角膜症
• 世界の持続性上皮欠損管理市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学火傷
• 外傷による欠陥
• 先天性角膜混濁

第7章 地域別・国別分析

• 世界の持続性上皮欠損管理市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の持続性上皮欠損管理市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 持続性上皮欠損管理市場：競合情勢
• 持続性上皮欠損管理市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Vision Overview, Products and Services, Strategy and Financial Analysis
  • RegeneRx Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Alcon Inc.
• Bausch Health Companies Inc.
• Hoya Vision Care
• Santen Pharmaceutical Co. Ltd.
• Recordati Rare Diseases Inc.
• Dompe Farmaceutici S.p.A.
• Lumenis Ltd.
• TissueTech Inc.
• Ocular Therapeutix Inc.
• Oculus Surgical Inc.
• Amber Ophthalmics Inc.
• Noveome Biotherapeutics Inc.
• OcuNexus Therapeutics Inc.
• Lux Bio Inc.
• Eyenovia Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 持続性上皮欠損管理市場2029：新たな機会を提供する国
• 持続性上皮欠損管理市場2029：新たな機会を提供するセグメント
• 持続性上皮欠損管理市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Persistent Epithelial Defect (PED) Management encompasses medical strategies aimed at promoting corneal healing when the corneal epithelium fails to regenerate and close within two weeks despite standard treatment. This approach involves identifying and addressing underlying causes while utilizing therapeutic methods such as lubricating eye drops, autologous serum tears, amniotic membrane transplantation, bandage contact lenses, and biologic therapies. These interventions help facilitate epithelial healing and prevent complications such as corneal ulcers or perforation.

The primary disease categories in persistent epithelial defect management include epithelial or limbal conditions, inflammatory diseases, neurotrophic diseases, and other related conditions. Epithelial and limbal disorders impact the corneal epithelium and limbal stem cells, resulting in vision-threatening defects due to impaired corneal regeneration. Medications are distributed through various channels, including direct sales, online pharmacies, retail pharmacies, and hospitals. These drugs serve different end users, such as hospital or clinical laboratories, physician offices, reference laboratories, and other medical institutions.

The persistent epithelial defect management market research report is one of a series of new reports from The Business Research Company that provides persistent epithelial defect management market statistics, including the persistent epithelial defect management industry global market size, regional shares, competitors with the persistent epithelial defect management market share, detailed persistent epithelial defect management market segments, market trends, and opportunities, and any further data you may need to thrive in the persistent epithelial defect management industry. This persistent epithelial defect management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The persistent epithelial defect management market size has grown rapidly in recent years. It will grow from $7.92 billion in 2024 to $9.29 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth during the historic period can be attributed to increased research activities, a higher demand for hospitals, a rising prevalence of ocular surface disorders, a growing incidence of eye diseases, and an aging population.

The persistent epithelial defect management market size is expected to see rapid growth in the next few years. It will grow to $17.35 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The projected growth in the forecast period is driven by increased partnerships and collaborations, greater awareness and education, a focus on value-based care, the rising prevalence of conditions such as diabetes and hypertension, and early intervention and management. Key trends include technological advancements, a growing demand for innovative treatment options, advanced treatment modalities, the availability of cutting-edge surgical tools and techniques, and the development of innovative drugs.

The growing prevalence of eye disorders is anticipated to drive the expansion of the persistent epithelial defect management market. Eye disorders encompass a wide range of medical conditions that impact the structure, function, or overall health of the eyes, leading to vision impairment, discomfort, or potential blindness. Factors such as aging populations, prolonged screen exposure, and environmental changes contribute to the rising prevalence of these conditions. Effective management of persistent epithelial defects is crucial for treating eye disorders, as it facilitates healing, reduces inflammation, and prevents complications such as infection or scarring. For example, in December 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that the overall pooled prevalence of childhood myopia was 5.23% in 2023, with a notably higher rate among females (4.90%) compared to males (3.94%). As a result, the increasing occurrence of eye disorders is fueling the growth of the persistent epithelial defect management market.

The growing number of eye surgeries is also expected to boost the persistent epithelial defect management market. Eye surgeries involve medical procedures performed to correct vision problems, treat diseases, or repair injuries. This increase in surgical procedures is driven by the rising prevalence of eye disorders such as cataracts, glaucoma, and refractive errors, alongside advancements in surgical techniques and the widespread adoption of minimally invasive procedures. Effective persistent epithelial defect management plays a vital role in eye surgeries by promoting corneal healing, reducing complications, and enhancing visual outcomes through targeted treatments that support epithelial regeneration. For instance, in 2023, the Eye Bank Association of America, a US-based transplant association, reported a 2.7% increase in domestic keratoplasty procedures, rising from 49,597 in 2022 to 50,925 in 2023. This growing trend in eye surgeries is contributing to the expansion of the persistent epithelial defect management market.

Leading companies in the persistent epithelial defect management market are focusing on innovative treatments such as secretome therapy to accelerate healing and enhance treatment outcomes. Secretome therapy involves using bioactive molecules secreted by cells, including proteins, lipids, and extracellular vesicles, to promote tissue repair, modulate immune responses, and treat various diseases. For example, in April 2023, Kala Pharmaceuticals Inc., a US-based biopharmaceutical company, received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for KPI-012, a human MSC-S therapy designed for persistent corneal epithelial defects. This therapy employs a multifactorial mechanism of action to address all underlying causes of persistent epithelial defects by facilitating corneal healing through bioactive molecules such as growth factors, protease inhibitors, and neurotrophic factors.

Major players in the persistent epithelial defect management market are AbbVie Inc., Novartis AG, Johnson & Johnson Vision, RegeneRx Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Vision Care, Santen Pharmaceutical Co. Ltd., Recordati Rare Diseases Inc., Dompe Farmaceutici S.p.A., Lumenis Ltd., TissueTech Inc., Ocular Therapeutix Inc., Oculus Surgical Inc., Amber Ophthalmics Inc., Noveome Biotherapeutics Inc., OcuNexus Therapeutics Inc., Lux Bio Inc., Eyenovia Inc.

North America was the largest region in the persistent epithelial defect management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in persistent epithelial defect management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the persistent epithelial defect management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The persistent epithelial defect management market consists of revenues earned by entities by providing services such as pharmacological treatments, amniotic membrane transplantation, bandage contact lenses, and tarsorrhaphy procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The persistent epithelial defect management market also includes sales of autologous serum eye drops, regenerative biologic eye drops, bandage contact lenses, and amniotic membrane grafts. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Persistent Epithelial Defect Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on persistent epithelial defect management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for persistent epithelial defect management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The persistent epithelial defect management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Epithalial Or Limbal; Inflammatory Disease; Neurotrophic Disease; Other Disease Types
• 2) By Distribution Channel: Direct Sales; Online Pharmacy; Retail Pharmacy; Hospitals
• 3) By End User: Hospital Or Clinical Laboratories; Physician Offices; Reference Laboratories; Other End Users
• Subsegments:
• 1) By Epithelial Or Limbal: Limbal Stem Cell Deficiency (LSCD); Limbal Transplantation; Conjunctival Transplantation
• 2) By Inflammatory Disease: Dry Eye Syndrome; Allergic Conjunctivitis; Uveitis
• 3) By Neurotrophic Disease: Herpes Simplex Virus (HSV) Keratitis; Diabetic Neuropathy; Neurotrophic Keratopathy
• 4) By Other Disease Types: Chemical Burns; Trauma-Induced Defects; Congenital Corneal Opacities
• Companies Mentioned:AbbVie Inc.; Novartis AG; Johnson & Johnson Vision; RegeneRx Biopharmaceuticals Inc.; Regeneron Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Persistent Epithelial Defect Management Market Characteristics

3. Persistent Epithelial Defect Management Market Trends And Strategies

4. Persistent Epithelial Defect Management Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Persistent Epithelial Defect Management Growth Analysis And Strategic Analysis Framework

• 5.1. Global Persistent Epithelial Defect Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Persistent Epithelial Defect Management Market Growth Rate Analysis
• 5.4. Global Persistent Epithelial Defect Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Persistent Epithelial Defect Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Persistent Epithelial Defect Management Total Addressable Market (TAM)

6. Persistent Epithelial Defect Management Market Segmentation

• 6.1. Global Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithalial Or Limbal
• Inflammatory Disease
• Neurotrophic Disease
• Other Disease Types
• 6.2. Global Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Online Pharmacy
• Retail Pharmacy
• Hospitals
• 6.3. Global Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Or Clinical Laboratories
• Physician Offices
• Reference Laboratories
• Other End Users
• 6.4. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Epithelial Or Limbal, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Limbal Stem Cell Deficiency (LSCD)
• Limbal Transplantation
• Conjunctival Transplantation
• 6.5. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Inflammatory Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Eye Syndrome
• Allergic Conjunctivitis
• Uveitis
• 6.6. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Neurotrophic Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Herpes Simplex Virus (HSV) Keratitis
• Diabetic Neuropathy
• Neurotrophic Keratopathy
• 6.7. Global Persistent Epithelial Defect Management Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemical Burns
• Trauma-Induced Defects
• Congenital Corneal Opacities

7. Persistent Epithelial Defect Management Market Regional And Country Analysis

• 7.1. Global Persistent Epithelial Defect Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Persistent Epithelial Defect Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Persistent Epithelial Defect Management Market

• 8.1. Asia-Pacific Persistent Epithelial Defect Management Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Persistent Epithelial Defect Management Market

• 9.1. China Persistent Epithelial Defect Management Market Overview
• 9.2. China Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Persistent Epithelial Defect Management Market

• 10.1. India Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Persistent Epithelial Defect Management Market

• 11.1. Japan Persistent Epithelial Defect Management Market Overview
• 11.2. Japan Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Persistent Epithelial Defect Management Market

• 12.1. Australia Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Persistent Epithelial Defect Management Market

• 13.1. Indonesia Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Persistent Epithelial Defect Management Market

• 14.1. South Korea Persistent Epithelial Defect Management Market Overview
• 14.2. South Korea Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Persistent Epithelial Defect Management Market

• 15.1. Western Europe Persistent Epithelial Defect Management Market Overview
• 15.2. Western Europe Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Persistent Epithelial Defect Management Market

• 16.1. UK Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Persistent Epithelial Defect Management Market

• 17.1. Germany Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Persistent Epithelial Defect Management Market

• 18.1. France Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Persistent Epithelial Defect Management Market

• 19.1. Italy Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Persistent Epithelial Defect Management Market

• 20.1. Spain Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Persistent Epithelial Defect Management Market

• 21.1. Eastern Europe Persistent Epithelial Defect Management Market Overview
• 21.2. Eastern Europe Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Persistent Epithelial Defect Management Market

• 22.1. Russia Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Persistent Epithelial Defect Management Market

• 23.1. North America Persistent Epithelial Defect Management Market Overview
• 23.2. North America Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Persistent Epithelial Defect Management Market

• 24.1. USA Persistent Epithelial Defect Management Market Overview
• 24.2. USA Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Persistent Epithelial Defect Management Market

• 25.1. Canada Persistent Epithelial Defect Management Market Overview
• 25.2. Canada Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Persistent Epithelial Defect Management Market

• 26.1. South America Persistent Epithelial Defect Management Market Overview
• 26.2. South America Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Persistent Epithelial Defect Management Market

• 27.1. Brazil Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Persistent Epithelial Defect Management Market

• 28.1. Middle East Persistent Epithelial Defect Management Market Overview
• 28.2. Middle East Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Persistent Epithelial Defect Management Market

• 29.1. Africa Persistent Epithelial Defect Management Market Overview
• 29.2. Africa Persistent Epithelial Defect Management Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Persistent Epithelial Defect Management Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Persistent Epithelial Defect Management Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Persistent Epithelial Defect Management Market Competitive Landscape And Company Profiles

• 30.1. Persistent Epithelial Defect Management Market Competitive Landscape
• 30.2. Persistent Epithelial Defect Management Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Vision Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. RegeneRx Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Persistent Epithelial Defect Management Market Other Major And Innovative Companies

• 31.1. Alcon Inc.
• 31.2. Bausch Health Companies Inc.
• 31.3. Hoya Vision Care
• 31.4. Santen Pharmaceutical Co. Ltd.
• 31.5. Recordati Rare Diseases Inc.
• 31.6. Dompe Farmaceutici S.p.A.
• 31.7. Lumenis Ltd.
• 31.8. TissueTech Inc.
• 31.9. Ocular Therapeutix Inc.
• 31.10. Oculus Surgical Inc.
• 31.11. Amber Ophthalmics Inc.
• 31.12. Noveome Biotherapeutics Inc.
• 31.13. OcuNexus Therapeutics Inc.
• 31.14. Lux Bio Inc.
• 31.15. Eyenovia Inc.

32. Global Persistent Epithelial Defect Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Persistent Epithelial Defect Management Market

34. Recent Developments In The Persistent Epithelial Defect Management Market

35. Persistent Epithelial Defect Management Market High Potential Countries, Segments and Strategies

• 35.1 Persistent Epithelial Defect Management Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Persistent Epithelial Defect Management Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Persistent Epithelial Defect Management Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer